Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020
- New data from the randomized placebo-controlled study CaLIPSO will describe consistent effect of SNF472 in slowing progression of coronary arterial calcification in ESKD patients on hemodialysis across key subgroups.
- New analysis of the data from CaLIPSO will show exposure-efficacy relationship between the agent and progression of coronary calcification.
- Design of the recently initiated phase 3 study in calciphylaxis (CALCIPHYX).
- Preclinical data evaluating inhibition of valvular calcification in porcine valve leaflets.
The meeting will run from October 22-25 2020 and will be fully virtual, with further information available on the ASN website. Full details of the abstracts are as follows:
Oral Presentation:
Title: SNF472 Consistently Slows Progression of Coronary Artery Calcification Across Subgroups of Patients on Hemodialysis
Date & Time: Thursday, October 22, from 17.00-19.00 p.m. EDT
Presentation Code: OR0401
[Link to Abstract]
ePoster Sessions:
Title: Design of the CALCIPHYX Study, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SNF472 for Treating Calciphylaxis
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: INFO07
[Link to Abstract]
Title: PK-PD and exposure-efficacy evaluation from CaLIPSO, a phase 2B study to assess the effect of SNF472 on progression of cardiovascular calcification in patients on hemodialysis
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: PO1142
[Link to Abstract]
Title: SNF472 inhibits heart valve calcification in a novel in vitro method using porcine whole leaflets
Date & Time: Thursday, October 22, 10:00 a.m. EDT
ePoster Code: PO0320
[Link to Abstract]
For further enquiries:
Sanifit
Joan Perelló, CEO
Antonio Jiménez, VP Operations
For media enquiries:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700
Email: sanifit@consilum-comms.com
About Sanifit
Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. The company’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease in end-stage kidney disease patients as a second indication for SNF 472. For more information, please visit www.sanifit.com.